Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.28 CAD | -0.24% | -0.24% | -8.20% |
03-08 | National Bank Reviews KP Tissue's Q4 Results | MT |
03-07 | KP Tissue Swings to Profit in Q4; Declares Dividend; Kruger Products' Q4 Profit, Revenue Climbs | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.6 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- One of the major weak points of the company is its financial situation.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.20% | 60.29M | D | ||
+11.30% | 45.54B | B- | ||
-9.06% | 17.38B | A- | ||
+3.08% | 3.6B | B- | ||
-3.85% | 2.44B | - | C- | |
-13.60% | 1.56B | C- | ||
+40.30% | 1.26B | - | ||
+13.83% | 928M | - | ||
+24.39% | 820M | B | ||
+25.47% | 436M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KPT Stock
- Ratings KP Tissue Inc.